Sign Up Today and Learn More About Lykos Therapeutics Stock
Invest in or calculate the value of your shares in Lykos Therapeutics or other pre-IPO companies through EquityZen's platform.
Lykos Therapeutics Stock
Lykos Therapeutics catalyzes healing and well-being through psychedelic drug development, therapist training programs.
About Lykos Therapeutics Stock
Founded
2014
Headquarters
San Jose, CA, US
Industries
Health Care, Education, Information Technology
Lykos Therapeutics Press Mentions
Stay in the know about the latest news on Lykos Therapeutics
PE Plays It Safe in Psychedelic Investments While Venture Goes Bold
bhbusiness • Aug 21, 2025
Former Burning Man Project and MAPS General Counsel Raymond Allen Joins Antithesis Law
prnewswire • Jul 17, 2025
Can Psychedelics Break Through in Depression? Recent Readouts Leave Investors Wanting More
biospace • Jul 14, 2025
Post-Traumatic Stress Disorder Epidemiology and Strategic Analysis Highlight Growth Opportunities in PTSD Market
globenewswire • Jun 05, 2025
Psychedelic Science 2025 Expands Business Track, Announces Select Speakers and Featured Sessions
globenewswire • May 08, 2025
Lykos Therapeutics Management
Leadership team at Lykos Therapeutics
CFO
Andrew "Mo" Septimus
CEO
Amy Emerson
Join now and verify your accreditation status to gain access to:
- Lykos Therapeutics Current Valuation
- Lykos Therapeutics Stock Price
- Lykos Therapeutics Management
- Available deals in Lykos Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Lykos Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Lykos Therapeutics Revenue and Financials
- Lykos Therapeutics Highlights
- Lykos Therapeutics Business Model
- Lykos Therapeutics Risk Factors
- Lykos Therapeutics Research Report from SACRA Research
Trading Lykos Therapeutics Stock
How to invest in Lykos Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Lykos Therapeutics through EquityZen funds. These investments are made available by existing Lykos Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Lykos Therapeutics stock?
Shareholders can sell their Lykos Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 390K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 48K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."